Introduction & Objective: Today, most patients with T1D in the US are OW or OB, contributing to insulin resistance and suboptimal glucose control. The only FDA approved treatment for T1D, insulin, adversely affects weight. Tirzepatide is approved for managing T2D and causes weight loss. We assessed the use of tirzepatide in OW/OB subjects with T1D.
Methods: This was a retrospective single center real-world study in 62 adult OW/OB patients with T1D who were prescribed tirzepatide and followed for one year. The control group included 37 T1D patients (computer matched) with OW or OB who were not using any weight loss medications during the same period.
Results: The mean baseline age, duration of diabetes and HbA1c were similar in the 2 groups (Table 1a), while BMI and weight were higher in cases. There were significantly larger declines in BMI and weight in cases than controls across all time points (Table 1b). HbA1c decreased in cases as early as 3 months which was sustained throughout 1-year follow-up (Table 1 b). There was no reported increase in severe hypoglycemia or diabetic ketoacidosis throughout the study duration.
Conclusions: In this pilot off-label use study, we conclude that tirzepatide facilitated an average 18.5% weight loss and improved glucose control in OW/OB patients with T1D. We strongly recommend a large prospective randomized control trial in OW/OB patients with T1D.
J.K. Snell-Bergeon: None. G. Kaur: None. C. Beatson: None. S.K. Garg: Research Support; Eli Lilly and Company. Advisory Panel; Medtronic. Research Support; Medtronic. Advisory Panel; Novo Nordisk. Research Support; DarioHealth Corp., Dexcom, Inc., Diasome. Advisory Panel; Roche Diabetes Care.
